罗伊乳杆菌LE16益生特性的研究

目的研究罗伊乳杆菌LE16的益生特性。方法通过体外和动物实验,评价罗伊乳杆菌LE16的益生特性。结果该菌株对p H 2.5的强酸和0.3%高胆盐环境均有良好的耐受性。对引起肠道感染的几种病原菌均有不同程度的拮抗,尤其对枯草芽胞杆菌、伤寒沙门菌、单核细胞增生李斯特菌及蜡样芽胞杆菌的抑制作用最强。对肠道菌群正常和失调的小鼠均具有调节功能。结论罗伊乳杆菌LE16具有良好的益生性能,可作为益生菌菌株开发应用于食品和保健食品中。     

Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri

We examined the competition of binding of Lactobacillus reuteri and Helicobacter pylori to gangliotetraosylceramide (asialo-GM1) and sulfatide which are putative glycolipid receptor molecules of H. pylori, and identified a possible sulfatide-binding protein of the L. reuteri strain. Among nine L. reuteri strains, two (JCM1081 and TM105) were shown to bind to asialo-GM1 and sulfatide, and to inhibit binding of H. pylori to both glycolipids by a thin layer chromatogram-overlay assay using biotin-labeled bacterial cells. The extract from the bacterial cells of strain TM105 with several detergents, including octyl beta-D-glucopyranoside, retained binding to both glycolipids and also inhibited H. pylori binding, suggesting that a binding inhibitor(s) is associated with the bacterial cell surface. When the cell extract was applied to the agarose gel immobilized galactose 3-sulfate corresponding to the structure of sugar moieties of sulfatide, an approximately 47-kDa protein was found to bind to the gel. This observation strongly suggested that inhibition by selected L. reuteri strains help to prevent infection in an early stage of colonization in H. pylori and proposed that L. reuteri strains sharing glycolipid specificity with H. pylori have a potential as probiotics.     

罗伊乳杆菌对致龋变形链球菌拮抗作用的研究

目的研究罗伊乳杆菌对变形链球菌的拮抗作用,初步了解产生拮抗作用的原因。方法利用罗伊乳杆菌无菌上清液,应用双层平板打孔法测定其抑菌效果,再通过滤纸片抑菌法对罗伊乳杆菌发酵的酸乳制品与普通酸乳制品对变形链球菌的抑菌作用进行比较,用饱和硫酸铵沉淀法分析产生拮抗作用的原因。结果罗伊乳杆菌有显著抑菌活性（P〈0.05）,仅罗伊乳杆菌的发酵乳样品对变性链球菌产生直径为6.3mm抑菌圈,80%饱和硫酸铵沉淀的细菌素抑菌活力最强,蛋白酶K处理后无明显抑菌圈。结论本研究证明了罗伊乳杆菌的代谢产物以及罗伊乳杆菌发酵的酸奶制品对致龋菌变形链球菌有着明显的拮抗作用。     

罗伊乳酸杆菌甘油脱水酶基因的克隆及其在大肠杆菌中的表达

迅速升温的生物柴油投资热导致了其副产物甘油的大量积累,这一现状使得开发和利用甘油生产各种精细化工产品备受关注。本实验通过构建基因工程菌来生物转化甘油生产3-羟基丙醛,为甘油下游产品的开发开辟了一条新途径。3-羟基丙醛是一种重要的化学中间体,同时也是一种有效的抗菌剂和生物组织的固定剂,在化学工业中具有广泛的应用前景。实验主要利用甘油脱水酶N末端序列,并根据NCBI中公布的甘油脱水酶的氨基酸序列设计了一对克隆引物,并以菌株罗伊乳酸杆菌Lactobacillus reuteri的基因组DNA为模板进行PCR扩增,获得约为1.6kb的片段,将其克隆到T载体上进行测序,对测序结果进行分析,重新设计两端含有EcoRI和HindIII酶切位点的表达引物,利用PCR扩增得到了甘油脱水酶基因,该基因片段长度为1674bp,编码558个氨基酸。将所得片段定向克隆到pET28b载体中,并转化至大肠杆菌BL21感受态细胞中。经IPTG诱导后,进行SDS-PAGE电泳,在约65kD处检测出一蛋白表达条带,另外还对该重组菌进行比活力测定,最高比活力可达1.14U/mg,比野生型菌株提高了86.88%。     

Metabolic pathway of α‐ketoglutarate in Lactobacillus sanfranciscensis and Lactobacillus reuteri during sourdough fermentation

Aim: To identify metabolites of α‐ketoglutarate (α‐KG) in Lactobacillus sanfranciscensis and Lactobacillus reuteri in modified MRS and sourdough. Methods and Results: Lactobacillus sanfranciscensis and L. reuteri were grown with additional α‐KG in mMRS and in wheat sourdough. In mMRS, α‐KG was used as an electron acceptor and converted to 2‐hydroxyglutarate (2‐OHG) by both organisms. Production of 2‐OHG was identified by high performance liquid chromatography (HPLC) and confirmed by gas chromatography (GC). Crude cell extracts of L. sanfranciscensis and L. reuteri grown with or without α‐KG exhibited OHG dehydrogenase activity of 6·3 ± 0·3, 2·3 ± 0·9, 1·2 ± 0·2, and 1·1 ± 0·1 mmol l^?1 NADH (min x mg protein)^?1, respectively. The presence of phenylalanine and citrate in addition to α‐KG partially redirected the use of α‐KG from electron acceptor to amino group acceptor. In wheat sourdoughs, α‐KG was predominantly used as electron acceptor and converted to 2‐OHG. Conclusions: Lactobacillus sanfranciscensis and L. reuteri utilize α‐KG as electron acceptor. Alternative use of α‐KG as amino group acceptor occurs in the presence of abundant amino donors and citrate. Significance and Impact of the Study: The use of α‐KG as electron acceptor in heterofermentative lactobacilli impacts the formation of flavour volatiles through the transamination pathway.     

The cell surface of Lactobacillus reuteri ATCC 55730 highlighted by identification of 126 extracellular proteins from the genome sequence

Bioinformatical analyses of a draft genome sequence of the commensal bacterium Lactobacillus reuteri ATCC 55730 revealed 126 genes encoding putative extracellular proteins. The function, localization and distribution in bacterial species were predicted. Interestingly, few proteins possessed LPXTG motifs or C-terminal transmembrane anchors. Instead eight proteins were putatively anchored by GW repeats and several secreted proteins were likely to be re-associated to the surface. The majority of the extracellular proteins were widely distributed, i.e., found universally or in gram-positive bacteria, but 24 were only detected in L. reuteri. Further, the number of transporters was lower, while the number of enzyme was higher than in related species.     

Inhibition of growth of Trichophyton tonsurans by Lactobacillus reuteri

Aim: The aims of this study were to identify antifungal lactic acid bacteria (LAB) and characterize their activity against the dermatophyte Trichophyton tonsurans. Methods and Results: A total of 165 different LAB were isolated and initially screened for anti‐Penicillium expansum activity. Five strains, which exhibited strong inhibitory activity, were then tested against the dermatophyte T. tonsurans DSM12285, where they also caused inhibition as observed by large fungal clearing on agar surface. The strongest inhibition was seen with Lactobacillus reuteri R2. When freeze‐dried cell‐free supernatant powder from this strain was incorporated in culture medium at concentrations >1%, growth of fungal colony was inhibited. Conidia germination was also inhibited under these conditions as determined by microscopy. The anti‐T. tonsurans activity of Lact. reuteri R2 was not affected neither by heat treatment nor by proteolytic treatment using pronase E and proteinase K, indicating that the responsible agent(s) were nonproteinaceous in nature. Conclusions: Lactobacillus reuteri R2 was identified as having strong inhibitory activity against the dermatophyte T. tonsurans DSMZ12285. Significance and Impact of the Study: LAB are naturally associated with many foods and are well recognized for their biopreservative properties. The use of these and/or their products may well provide alternative safe approaches for the inhibition of dermatophytic fungi.     

Mice protected by oral immunization with Lactobacillus reuteri secreting fusion protein of Escherichia coli enterotoxin subunit protein

A green fluorescent protein (gfp) gene was ligated to the Lactobacillus reuteri-specific nisin-inducible expression-secretion vector pNIES, generating a pNIES-GFP vector capable of secreting the cloned gene as a GFP-fusion protein with fluorescent activity. To develop this system as a live vehicle carrying the heat-stable enterotoxin (ST) and heat-labile enterotoxin B (LT(B)) of the enterotoxigenic Escherichia coli (ETEC), a recombinant 5'-ST-LT(B)-3' DNA fragment was cloned into pNIES-GFP. The resulting L. reuteri/pNIES-GFP:STLT(B) system was found to possess the capability of adhering to the mice gut, secreting GFP:STLT(B) product at 0.14 and 0.026 pgcell(-1) under induced and noninduced conditions, respectively. Further analysis of the GFP:STLT(B) product confirmed its ganglioside-binding ability, LT(B) antigenicity and relative freedom from the ST-associated toxicity, making it suitable for use as an oral vaccine in mice. Oral inoculation of the L. reuteri/pNIES-GFP:STLT(B) culture in mice elicited significant (P<0.01) serum IgG and mucosal IgA antibodies against the STLT(B) antigen. These immunized mice were subsequently challenged with ETEC and showed full protection against the fluid influx response in the gut. This is the first report of using L. reuteri as a vaccine carrier to induce complete immunologic protection against ETEC.     

Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum

Aims:  The study aimed to identify the resistance genes mediating atypical minimum inhibitory concentrations (MICs) for tetracycline, erythromycin, clindamycin and chloramphenicol within two sets of representative strains of the species Lactobacillus reuteri and Lactobacillus plantarum and to characterize identified genes by means of gene location and sequencing of flanking regions.
Methods and Results:  A tet (W) gene was found in 24 of the 28 Lact. reuteri strains with atypical MIC for tetracycline, whereas four of the six strains with atypical MIC for erythromycin were positive for erm (B) and one strain each was positive for erm (C) and erm (T). The two Lact. plantarum strains with atypical MIC for tetracycline harboured a plasmid-encoded tet (M) gene. The majority of the tet (W)-positive Lact. reuteri strains and all erm -positive Lact. reuteri strains carried the genes on plasmids, as determined by Southern blot and a real-time PCR method developed in this study.
Conclusions:  Most of the antibiotic-resistant strains of Lact. reuteri and Lact. plantarum harboured known plasmid-encoded resistance genes. Examples of putative transfer machineries adjacent to both plasmid- and chromosome-located resistance genes were also demonstrated.
Significance and Impact of the Study:  These data provide some of the knowledge required for assessing the possible risk of using Lact. reuteri and Lact. plantarum strains carrying antibiotic resistance genes as starter cultures and probiotics.     

罗伊氏乳杆菌的益生功能

罗伊氏乳杆菌是目前已报道的几乎可存在于所有脊椎动物和哺乳动物肠道内的乳酸杆菌,是具有益生功效的肠道益生菌.通过对罗伊氏乳杆菌良好的肠道定植能力和其产生的罗伊氏菌素的介绍,阐明其可能的益生作用机理.重点论述了罗伊氏乳杆菌促进人类和动物健康功能的研究进展,并探讨了今后罗伊乳杆菌益生菌制剂的工业化发展趋势.     

罗伊乳杆菌对小鼠血清细胞因子含量和肠道菌群的影响

目的 探讨罗伊乳杆菌对小鼠免疫力及肠道菌群的影响。方法 将50只昆明系小鼠按体重随机分成5组：空白对照组、低剂量组、中剂量组、高剂量组和发酵上清液组。空白对照组灌胃等量生理盐水,其余各组分别灌胃罗伊乳杆菌菌液及发酵液上清21 d后,眼球取血收集血清,采用ELISA法检测IL-2、IFN-γ、IgA和IgG含量;采用16S rRNA基因高通量测序分析小鼠肠道菌群变化。结果 与对照组相比,其余各组小鼠血清IL-2、IFN-γ、IgA和IgG的水平均明显升高,粪便菌群丰度有所增高,多样性降低。与对照组相比,低剂量组和中剂量组小鼠粪便菌群结构无显著差异,而高剂量组和发酵上清液组小鼠粪便菌群结构差异显著。结论 罗伊乳杆菌可以增强小鼠免疫力,提高菌群丰度,改变小鼠肠道菌群结构。     

罗氏乳杆菌无细胞上清培养液移除胆固醇能力的研究

本文探讨了罗氏乳杆菌DSM122460无细胞上清培养液(Cell-Free Supernatant,CFS)移除胆固醇的能力。采用邻苯二甲醛法测定DSM122460和对照菌株ST-III发酵过程中及其CFS对胆固醇的移除能力,并研究不同CFS浓度下的移除能力。并采用HPLC法测定CFS对照、热处理组和pH7.0组的胆盐水解酶活力,同时测定其移除胆固醇能力。结果显示,DSM122460不仅在发酵过程中具有较高的移除胆固醇能力,其CFS也表现出较高的移除能力,CFS中含有除胆盐水解酶以外的可移除胆固醇的蛋白类成分。这提示可能存在一种乳酸菌移除胆固醇的新机制。     

罗伊氏乳杆菌辅助治疗种植体周围炎的临床和微生物学疗效

目的 探究罗伊氏乳杆菌辅助治疗种植体周围炎（PIS）的临床疗效,并分析治疗后种植体周围的微生物环境。方法 86例2016年12月—2018年12月于我院就诊的PIS患者,按照随机数字表法将所有患者分为常规组（n=43）和联合组（n=43）。所有患者均给予一次牙周基础治疗及种植体清洗治疗,而联合组在此基础上增加口服拜奥益生菌滴剂（主要成分为罗伊氏乳杆菌）,共计治疗90 d。而后于治疗前后分别对比两组患者出血指数（BI）、菌斑指数（PLI）、种植体临床冠高度、种植体探诊深度以及以上4组数据于两个时间点间的差值。同时,取患者种植体周围口袋中分泌物,并分析其治疗前后龈沟液中细胞因子间的差异;根据以往经验,采用real-time PCR技术分析标本中常见致病菌的负荷量。结果 联合组治疗后BI显著低于常规组（P<0.05）,两组患者治疗前后BI、PLI及种植体周围探诊深度等指标比较差异具有统计学意义（均P<0.05）;联合组治疗后龈沟液中IL-1β、IL-6、TNF-α和MMP-8均显著低于常规组（均P<0.05）;联合组治疗前后福赛斯拟杆菌及牙龈卟啉单胞菌负荷量差异具有统计学意义（均P<0.05）。结论 罗伊氏乳杆菌辅助治疗PIS能更有效缓解患者症状,同时调节种植体周围细胞因子及微生物环境,对PIS有较好的治疗作用。     

罗伊氏乳杆菌(息敏乐)辅助治疗儿童功能性便秘的多中心研究

目的 探讨罗伊氏乳杆菌(息敏乐)辅助治疗儿童功能性便秘的临床疗效及安全性,为后续研究提供参考.方法 选择2016年6月至2018年6月期间5个研究中心收治的237例功能性便秘患儿为研究对象,按照随机数表法分为对照组(n=76)、观察A组(n=78)、观察B组(n=83).对照组患儿采用饮食调节及排便习惯锻炼等常规治疗,...     

Direct cloning of a xylanase gene from the mixed genomic DNA of rumen fungi and its expression in intestinal Lactobacillus reuteri

A relatively newly defined xylanase gene, xynR8, was obtained directly from a mixed DNA sample prepared from unpurified rumen fungal cultures by PCR amplification. The DNA sequence of xynR8 revealed that the gene was 884 bp in size and encoded amino acid sequences with a molecular weight of 27.9 kDa. XynR8 belonged to glycosyl hydrolase family 11, and the catalytic site residues were also found in its amino acid sequence. The main hydrolysis products of XynR8 were xylobiose, xylotriose and xylotetrose, which indicated that it belonged to the endoxylanases. The xynR8 gene was constructed so as to express and secrete under the control of the Lactococcus lactis lac A promoter and its secretion signal, and was transformed into L. reuteri Pg4, a strain isolated from the gastrointestinal tract of broiler chickens. The L. reuteri transformants harboring xynR8 not only acquired the capacity to break down xylan, but also maintained their high adhesion efficiency to mucin and mucus and their resistance to bile salts and acid.     

Freezing resistance improvement of Lactobacillus reuteri by using cell immobilization

Lactobacillus reuteri shows certain beneficial effects to human health and is recognized as a probiotic. However, its application in frozen foods is still not popular because of its low survival during freezing and frozen storage. Cell immobilization technique could effectively exert protection effects to microbial cells in order to enhance their endurance to unfavorable environmental conditions as well as to improve their viability and cell concentration. Ca-alginate and κ-carrageenan were used to immobilize L. reuteri in this research, and the immobilized cells were exposed to different freezing temperatures, i.e. − 20 °C, − 40 °C, − 60 °C, − 80 °C, and stored at − 40 °C and − 80 °C for 12 weeks. The objectives were to study the protection effects of cell immobilization against the adverse conditions of freezing and frozen storage, and the effects of freezing temperatures to the immobilized cells. Cell immobilization was used to raise the survival of L. reuteri during freezing and frozen storage in order to develop frozen foods with the probiotic effects of L. reuteri. Results indicated that immobilized L. reuteri possessed better survival in both freezing and frozen storage. The survival of immobilized L. reuteri was higher than that of free cells, and the effects of lower freezing temperature were better than higher freezing temperature. The immobilization effects of Ca-alginate were found to be superior to κ-carrageenan. Cell immobilized L. reuteri exhibits potential to be used in frozen foods.     

Two-dimensional gel-based alkaline proteome of the probiotic bacterium Lactobacillus acidophilus NCFM

Lactobacillus acidophilus NCFM (NCFM) is a well-documented probiotic bacterium isolated from human gut. Detailed 2D gel-based NCFM proteomics addressed the so-called alkaline range, i.e., pH 6-11. Proteins were identified in 150 of the 202 spots picked from the Coomassie Brilliant Blue stained 2D gel using MALDI-TOF-MS. The 102 unique gene products among the 150 protein identifications were assigned to different functional categories, and evaluated by considering a calculated distribution of abundance as well as grand average of hydrophobicity values. None of the very few available lactic acid bacteria proteome reference maps included the range of pI >7.0. The present report of such data on the proteome of NCFM fundamentally complements current knowledge on protein profiles limited to the acid and neutral pH range.     

Inhibition of Helicobacter pylori Infection in Humans by Lactobacillus reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study

Background:  Several studies report an inhibitory effect of probiotics on Helicobacter pylori .
Aim:  To test whether Lactobacillus reuteri ATCC 55730 reduces H. pylori intragastric load in vivo, decreases dyspeptic symptoms, and affects eradication rates after conventional treatment.
Materials and Methods:  In a double-blind placebo-controlled study, 40 H. pylori -positive subjects were given L. reuteri once a day for 4 weeks or placebo. All underwent upper endoscopy, ¹³C-urea breath test, and H. pylori stool antigen determination at entry and ¹³C-urea breath test and H. pylori stool antigen (used as both qualitative and semiquantitative markers) after 4 weeks of treatment. Sequential treatment was administered subsequently to all.
Results:  In vivo, L. reuteri reduces H. pylori load as semiquantitatively assessed by both ¹³C-urea breath test δ -value and H. pylori stool antigen quantification after 4 weeks of treatment ( p <  .05). No change was shown in patients receiving placebo. L. reuteri administration was followed by a significant decrease in the Gastrointestinal Symptom Rating Scale as compared to pretreatment value ( p <  .05) that was not present in those receiving placebo ( p =  not significant). No difference in eradication rates was observed.
Conclusions:  L. reuteri effectively suppresses H. pylori infection in humans and decreases the occurrence of dyspeptic symptoms. Nevertheless, it does not seem to affect antibiotic therapy outcome.